Loading...
XSTO
IDLDX
Market cap11mUSD
Jun 23, Last price  
0.50SEK
Name

AroCell AB (publ)

Chart & performance

D1W1MN
XSTO:IDLDX chart
P/E
—
P/S
2.01
EPS
—
Div yield, %
—
Shrs. gr., 5y
41.80%
Rev. gr., 5y
164.62%
Revenues
57m
+33.45%
26,8540000460,21754,606502,033781,841442,69784,00011,996,00036,986,00043,039,00057,436,000
Net income
-42m
L-28.41%
-2,152,234-3,584,151-3,156,941-3,732,929-6,368,852-7,478,995-9,234,943-17,270,758-20,757,029-16,201,966-19,459,000-50,026,000-58,973,000-59,297,000-42,449,000
CFO
-2m
L-82.45%
-2,593,000000-9,127,552-7,167,532-15,235,183-16,407,394-15,055,220-18,902,000-28,206,000-13,694,000-13,436,000-2,358,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AroCell AB (publ) is an in vitro diagnostics enterprise primarily focused on the surveillance of various cancerous conditions, such as hematological malignancies, breast cancer, and other solid tumors. The company develops, produces, and markets its flagship product, AroCell TK 210 ELISA, an immunoassay kit designed for measuring Thymidine Kinase 1 levels in human blood. Additionally, AroCell provides TUBEX TF, a rapid bacteriological test for the detection of typhoid fever. Founded in 2000, the firm was originally known as Xi Bao Research AB, adopting its current name, AroCell AB (publ), in 2006. It maintains its headquarters in Uppsala, Sweden.

Key people

Anders Hultman
Chief Financial Officer · since 2018
Martin Shaw
Business Development Manager · since 2016
Kiran Kumar Jagarlamudi
Clinical Research Manager
Peter Lowendahl
Senior Director Regulatory Affairs · since 2019
Alf Malmberg
Manager QA&RA
Staffan Eriksson
Director
Karin Eriksson-Vidblom
Director · since 2019
Agneta Franksson
Director · since 2017
Gunnar Steineck
Director · since 2017
URL
https://arocell.com/
IPO date
May 25, 2011
Employees
26
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Karlsbodavägen 39
Bromma, AB 168 67
SE
Address
Karlsbodavagen 39
Bromma, AB 168 67
SE
Previous name
AroCell AB (publ)

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT